𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B

✍ Scribed by S. Gaia; A. Marzano; A. Smedile; V. Barbon; M. L. Abate; A. Olivero; M. Lagget; S. Paganin; M. Fadda; G. Niro; M. Rizzetto

Book ID
108603691
Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
119 KB
Volume
20
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical outcome of HBeAg-negative chron
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
✍ Dr. Vito Di Marco; Alfredo Marzano; Pietro Lampertico; Pietro Andreone; Teresa S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 869 KB

The effect of lamivudine treatment on the outcome of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis is unclear. In a retrospective multicenter study, we have analyzed the virological events observed during lamivudine therapy in patients with HBeAgnegative chronic hepatitis an

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60